Cargando…

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: Improving treatment strategies for refractory or relapsed advanced non-small-cell lung cancer (NSCLC) remains a challenge. Efficacy and safety of the immune checkpoint inhibitors (ICIs), nivolumab (Niv) plus atezolizumab (Atz), were compared with those of ramucirumab (Ram) plus docet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ando, Koichi, Manabe, Ryo, Kishino, Yasunari, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Ohnishi, Tsukasa, Sagara, Hironori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796092/ https://www.ncbi.nlm.nih.gov/pubmed/33561074 http://dx.doi.org/10.3390/cancers13010052

Ejemplares similares

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2021)

Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2021)

Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2023)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
por: Ohmori, Tohru, et al.
Publicado: (2021)

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2020)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury
por: Yamaoka, Toshimitsu, et al.
Publicado: (2019)

Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Inhibition of Virus-Induced Cytokine Production from Airway Epithelial Cells by the Late Addition of Budesonide
por: Homma, Tetsuya, et al.
Publicado: (2020)

Association between respiratory impedance measured by forced oscillation technique and exacerbations in patients with COPD
por: Yamagami, Hitomi, et al.
Publicado: (2017)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Improvement in Frailty in a Patient With Severe Chronic Obstructive Pulmonary Disease After Ninjin'yoeito Therapy: A Case Report
por: Kuniaki, Hirai, et al.
Publicado: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
por: Messeha, Samia S., et al.
Publicado: (2021)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_blf25ps85fi03jr9tod8ubr7lv